Wally Kopelowitz, MD
Ophthalmology · Brooklyn, NYNPI 1639128135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 24.8% of the total. Reporting peaked in 2019 at $209 and has fallen 84.1% since, to $33 in 2025. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.
Across 15 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$122
- Oyster Point Pharma, Inc.$119
- Alcon$97
- Sun Pharmaceutical Industries Inc.$39
- Tarsus Pharmaceuticals, Inc.$37
- Astellas Pharma US Inc$29
- plus $52 from 3 others
What the payments were for
- Food & beverage$494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $122 |
| Oyster Point Pharma, Inc. | 4 | $119 |
| Alcon | 1 | $97 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $37 |
| Astellas Pharma US Inc | 1 | $29 |
| Thea Pharma Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$494 in reported general payments places this provider in the 35th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $34,430 |
| XiidraLifitegrast | 36 | $26,428 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $20,545 |
| Alphagan PBrimonidine Tartrate | 12 | $3,523 |
| Brimonidine Tartrate | 115 | $3,425 |
| LumiganBimatoprost | 13 | $3,057 |
| Latanoprost | 459 | $2,614 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 113 | $1,450 |
| Prednisolone Acetate | 24 | $1,153 |
| Dorzolamide Hcl | 69 | $931 |
| Ketorolac Tromethamine | 48 | $809 |
| Azelastine Hcl | 68 | $778 |
| Timolol Maleate | 42 | $429 |
| ErythromycinErythromycin Base | 25 | $215 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$94K
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.